Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY).
about
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathyDual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular blockIntervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablationThe "missing" link between acute hemodynamic effect and clinical responseEmerging indications for permanent pacing.Permanent pacing: new indications.Cardiac pacing: how it started, where we are, where we are going.The diagnosis and treatment of hypertrophic cardiomyopathy.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm AssociPercutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of CareRescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes.Long-term mortality outcomes according to the frequency of right ventricular pacing in veterans.Analysis of dual-chamber pacing as a treatment for refractory limiting symptoms in patients with obstructive hypertrophic cardiomyopathy.Dual-chamber pacing in hypertrophic cardiomyopathy.Clinical and echocardiographic features of hypertrophic cardiomyopathy in the elderly.Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.Hypertrophic cardiomyopathy: a reviewWhat is new in pediatric cardiology.Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing.Intra- and interatrial conduction delay: implications for cardiac pacing.Obstructive hypertrophic cardiomyopathy.Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imagingRecent advances in diagnosis and management of hypertrophic cardiomyopathy.eComment. Septal reduction therapy for hypertrophic cardiomyopathy: the need of experienced centres.Implantable cardiac arrhythmia devices--part I: pacemakers.A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic cardiomyopathy in China.DDDR pacing for symptomatic patients with hypertrophic obstructive cardiomyopathy: The first experience in the Netherlands with pacing in HOCM.Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience.Anesthetic considerations in the patient with valvular heart disease undergoing noncardiac surgery.Contemporary treatment of hypertrophic cardiomyopathyModern pacemakers: hope or hype?Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic CardiomyopathyUnderstanding hypertrophic cardiomyopathy: implications of diagnosis for the patient and family.Device therapy in hypertrophic cardiomyopathy.Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients.Interventional treatments for hypertrophic cardiomyopathy.Almanac 2014: cardiomyopathies.Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy.Recent advances in genetics and treatment of hypertrophic cardiomyopathy.Feasibility of dual-chamber (DDD) pacing via a single-pass (VDD) pacing lead employing a floating atrial ring (dipole): case series, future considerations, and refinements.
P2860
Q24197872-338EE841-FCBD-463E-98D8-7E26FE58DE0BQ24247128-AA87EC8A-6511-4275-BEA8-4ED921DB9F07Q26773632-7F61A401-CE77-4343-BA40-771AD25AF7A9Q26824618-0D462996-2D28-486D-B7ED-D19E4330C2F0Q33145699-3939C83B-5235-424A-8405-ED3FC22C104DQ33146725-E4367236-D4B8-4969-BE06-7C29A0943D3BQ33151350-4C19478A-E8B9-4A25-9C95-16391A2D0277Q33159954-968589B6-788D-4CF2-87C8-9B2542B93B25Q33162947-80DEEA0E-F9E8-4092-9BE1-BEB1501BA7D7Q33166450-160849AF-69DE-443D-A179-9A374E3E723BQ33787794-0DEEE502-1D39-44D1-9379-7BC25564D81AQ33829448-59A8DB75-AD12-4FF0-869B-C3996D4F43F6Q34027451-5BEFA88B-5733-4797-9FD4-79B2B89CD9FBQ34027461-F2608EC5-C102-4545-A4AD-518400C8D2EEQ34286730-5921DB4F-CC91-452D-8898-5C500E0C24F4Q34460145-5F28C0F9-6613-430D-A0BA-A04967639411Q35024040-C870D966-36D6-4ADC-B879-0C007AFEAFEDQ35079114-E559FD5F-679B-43D4-A900-68F280350322Q35623368-9FB84E28-E349-4FB4-98AB-8F91BA401774Q35743815-1FE85F45-C578-4628-B10B-E4AB179A74AEQ35946809-08340881-1C3F-47A0-9972-581DA8EFB3BAQ35946887-09457220-FBE5-4F7A-8201-6B574ED9AF18Q36057471-BE99D247-03B6-4BAA-BEA5-2321CD5A8409Q36470597-D3277186-7CB5-4A5D-A0ED-9D666556C01EQ36494370-3618FD8A-4DF4-4C70-A0C2-18CF681AD90FQ36596751-A0D5447A-0148-43BA-9904-4C5338E4FFF4Q36817335-F8E0E41C-B4BC-49D5-A17A-C782EB9CAEB5Q36915921-4475CCFF-08F1-4CC1-AFBA-B1280A51100BQ37132526-BBC363CF-A0E2-4B60-AC13-7AA5E5CB75A0Q37227838-6F8B6583-C645-42C6-991B-4CEB1554FB95Q37589654-A74F92AA-63B1-4F3D-BAFB-80A7ADE86AE4Q37684990-508DC46A-D95B-4165-B870-581A43E7E295Q37735913-72BC6978-9829-4930-8D62-51D7AE1AC61AQ37812384-567BC6C8-6D96-43F7-A3D4-A21CF6E2EAC5Q37843011-313CAD9A-EF17-47DD-B354-37BFA545CD11Q37925001-BB9E6275-B3BC-46E0-8235-6AC4F780D884Q38193960-DEE838C5-832A-40A1-8D4D-13A4BDEF0D93Q38308920-E7579E52-2F96-411C-B486-6283209614C6Q39367648-AB51E7C8-3C2F-4E34-B2FB-09EECB2F04E5Q40423388-DB188855-3A11-410E-A20E-171731B7C286
P2860
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY).
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@en
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@nl
type
label
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@en
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@nl
prefLabel
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@en
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@nl
P2093
P1433
P1476
Assessment of permanent dual-c ...... nd, crossover study (M-PATHY).
@en
P2093
Josephson ME
McKenna WJ
Nishimura RA
Rakowski H
P304
P356
10.1161/01.CIR.99.22.2927
P407
P577
1999-06-01T00:00:00Z